Literature DB >> 18286475

Malignant tumors of blood vessels: angiosarcomas, hemangioendotheliomas, and hemangioperictyomas.

Moritz Koch1, G Petur Nielsen, Sam S Yoon.   

Abstract

Sarcomas that arise from or resemble the components of blood vessels are uncommon and include angiosarcomas, hemangioendotheliomas, and hemangiopericytomas. This article reviews the management of these three types of sarcomas. Diagnosis can sometimes be difficult, with the diagnosis of hemangiopericytoma versus solitary fibrous tumor currently in debate. Each of these sarcomas subtypes has certain unique clinical traits. The mainstay of treatment is surgical resection, sometimes combined with radiation therapy. Adjuvant chemotherapy is unproven but can be considered. For patients with advanced disease, various chemotherapeutic regimens may result in meaningful responses in a minority of patients. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2008        PMID: 18286475     DOI: 10.1002/jso.20973

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  33 in total

1.  Expression of cancer stem cell markers and their correlation with pathogenesis in vascular tumors.

Authors:  Jiaojiao Lan; Bing Huang; Ruixue Liu; Xinxin Ju; Yang Zhou; Jinfang Jiang; Weihua Liang; Yaoyuan Shen; Feng Li; Lijuan Pang
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

2.  Activation of endothelial ras signaling bypasses senescence and causes abnormal vascular morphogenesis.

Authors:  Anshika Bajaj; Qingxia Zheng; Alejandro Adam; Peter Vincent; Kevin Pumiglia
Journal:  Cancer Res       Date:  2010-04-13       Impact factor: 12.701

3.  ARF suppresses hepatic vascular neoplasia in a carcinogen-exposed murine model.

Authors:  Stephanie E Busch; Kay E Gurley; Russell D Moser; Christopher J Kemp
Journal:  J Pathol       Date:  2012-05-08       Impact factor: 7.996

4.  Differentiating primary hepatic angiosarcomas from hemangiomatosis and epithelioid hemangioendotheliomas using gadoxetic acid-enhanced and diffusion-weighted MR imaging.

Authors:  Jung Wook Seo; Seong Hyun Kim; Ah Yeong Kim; Woo Kyoung Jeong; Ji Young Woo; Won Jeong Park
Journal:  Jpn J Radiol       Date:  2017-09-06       Impact factor: 2.374

5.  Imatinib and Dasatinib Inhibit Hemangiosarcoma and Implicate PDGFR-β and Src in Tumor Growth.

Authors:  Erin B Dickerson; Kevin Marley; Wade Edris; Jeffrey W Tyner; Vidya Schalk; Valerie Macdonald; Marc Loriaux; Brian J Druker; Stuart C Helfand
Journal:  Transl Oncol       Date:  2013-04-01       Impact factor: 4.243

6.  Concurrent Cochlear Implantation with Resection of Skull Base Hemangiopericytoma following Sudden Deafness in an Only Hearing Ear.

Authors:  Evan R Ransom; Kevin D Judy; Douglas C Bigelow
Journal:  Skull Base       Date:  2010-07

7.  Angiosarcoma of the seminal vesicle: a case report of long-term survival following multimodality therapy.

Authors:  Kenneth Chang; Terence T Sio; Vishal S Chandan; Matthew J Iott; Christopher L Hallemeier
Journal:  Rare Tumors       Date:  2014-01-29

8.  Gene expression profiling identifies inflammation and angiogenesis as distinguishing features of canine hemangiosarcoma.

Authors:  Beth A Tamburini; Tzu L Phang; Susan P Fosmire; Milcah C Scott; Susan C Trapp; Megan M Duckett; Sally R Robinson; Jill E Slansky; Leslie C Sharkey; Gary R Cutter; John W Wojcieszyn; Donald Bellgrau; Robert M Gemmill; Lawrence E Hunter; Jaime F Modiano
Journal:  BMC Cancer       Date:  2010-11-09       Impact factor: 4.430

9.  Hemangiosarcoma and its cancer stem cell subpopulation are effectively killed by a toxin targeted through epidermal growth factor and urokinase receptors.

Authors:  Jill T Schappa; Aric M Frantz; Brandi H Gorden; Erin B Dickerson; Daniel A Vallera; Jaime F Modiano
Journal:  Int J Cancer       Date:  2013-04-25       Impact factor: 7.396

10.  Treatment of Recurrent Intracranial Hemangiopericytoma with SRC-Related Tyrosine Kinase Targeted Therapy: A Case Report.

Authors:  Katherine B Peters; Roger McLendon; Michael A Morse; James J Vredenburgh
Journal:  Case Rep Oncol       Date:  2010-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.